In this randomized controlled trial, among ischemic stroke patients treated with intravenous thrombolysis, it was found that ...

A newly found orthonairovirus, Wetland virus (WELV), was discovered to be pathogenic to humans, causing febrile illnesses in ...

1. A newly found orthonairovirus, Wetland virus (WELV), was discovered to be pathogenic to humans, causing febrile illnesses in northeastern... 1. In this randomized cluster trial, twice-yearly ...

In this secondary analysis of the MINT trial, 30-day risks for the composite outcome of death and recurrent myocardial ...

Major cardiac events were significantly lower in the OCT-guided group compared to the angiography-guided group. 2. Stroke, ...

In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal ...

In this randomized controlled trial, patients with metabolic syndrome who underwent time-restricted eating in addition to ...

The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Epkinly showed an overall response rate of 82% with 62.5% of patients achieving complete response. 65% of patients had grade 1-2 cytokine release syndrome (CRS), though severe cases (grade 3) were ...

Patients in the semaglutide group reported fewer heart failure events than those in the placebo group. 2. No significant ...

Afami-cel (Tecelra) is the first genetically engineered T-cell receptor therapy for synovial sarcoma Afami-cel demonstrated ...

Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2.